Combining amuvatinib and the epidermal growth factor receptor (EGFR) inhibitor erlotinib has also been shown to significantly inhibit tumor growth in PTEN-null LNCaP xenografts, accompanied by reduced AKT phosphorylation at S473 and T308 [311]. This evidence concerns the gene AKT1 and neoplasm.